IMAC vs. BEAT, CERS, MGTX, ANRO, LFMD, TNYA, SBTX, NAUT, SOPH, and ZYXI
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include BioTelemetry (BEAT), Cerus (CERS), MeiraGTx (MGTX), Alto Neuroscience (ANRO), LifeMD (LFMD), Tenaya Therapeutics (TNYA), Silverback Therapeutics (SBTX), Nautilus Biotechnology (NAUT), SOPHiA GENETICS (SOPH), and Zynex (ZYXI). These companies are all part of the "medical" sector.
IMAC (NASDAQ:IMAC) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
BioTelemetry has a consensus target price of $8.00, suggesting a potential upside of 187.77%. Given BioTelemetry's higher possible upside, analysts plainly believe BioTelemetry is more favorable than IMAC.
IMAC has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500.
24.3% of IMAC shares are held by institutional investors. Comparatively, 7.8% of BioTelemetry shares are held by institutional investors. 10.0% of IMAC shares are held by company insiders. Comparatively, 20.9% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, IMAC and IMAC both had 2 articles in the media. IMAC's average media sentiment score of 0.41 beat BioTelemetry's score of 0.00 indicating that IMAC is being referred to more favorably in the media.
IMAC has higher revenue and earnings than BioTelemetry.
BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.
BioTelemetry received 318 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.77% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote.
Summary
IMAC beats BioTelemetry on 7 of the 13 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
